Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?

J Gastroenterol Hepatol. 2013 Mar;28(3):479-87. doi: 10.1111/j.1440-1746.2012.07266.x.

Abstract

Background and aim: To examine the differences in esophageal histopathology between non-erosive reflux disease (NERD) and reflux esophagitis (RE), and to investigate whether baseline esophageal histopathology can predict the therapeutic response to proton pump inhibitors (PPIs).

Method: The subjects comprised 94 patients with NERD (n = 71) or mild RE (n = 23). Tissue was biopsied from 5 cm above the squamo-columnar junction (SCJ), and the degree or presence of nine histopathological markers was assessed. The patients were treated with rabeprazole (RPZ) 10 mg once daily for 4 weeks. If complete heartburn relief was not achieved, RPZ was increased to 10 mg twice daily for another 2 weeks, and then to 20 mg twice daily for another 2 weeks if heartburn remained.

Results: Features of esophageal histopathology 5 cm above the SCJ differed between NERD and RE patients. The esophageal histopathology in patients unresponsive to RPZ was characterized by Protein Gene Product (PGP) 9.5 negativity in those with NERD, and intraepithelial bleeding in those with RE. In addition, the combination of dilated intercellular spaces (DIS) (+)/PGP 9.5 (-) was indicative of strong resistance to PPI therapy in NERD patients.

Conclusion: The therapeutic efficacy of PPI can be predicted from the features of biopsied esophageal tissue. Factors predictive of resistance to treatment with PPI are negativity for PGP 9.5 in NERD patients and intraepithelial bleeding in RE patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / metabolism
  • Biopsy
  • Drug Administration Schedule
  • Esophagitis, Peptic / drug therapy
  • Esophagitis, Peptic / metabolism
  • Esophagitis, Peptic / pathology*
  • Esophagus / pathology*
  • Female
  • Gastroesophageal Reflux / drug therapy
  • Gastroesophageal Reflux / metabolism
  • Gastroesophageal Reflux / pathology*
  • Humans
  • Male
  • Middle Aged
  • Proton Pump Inhibitors / therapeutic use*
  • Rabeprazole
  • Treatment Outcome
  • Ubiquitin Thiolesterase / metabolism

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Biomarkers
  • Proton Pump Inhibitors
  • UCHL1 protein, human
  • Rabeprazole
  • Ubiquitin Thiolesterase